Biomarkers Market Companies and their Innovations
The biomarkers market size was estimated at US$ 82.35 billion in 2023 and is projected to grow to US$ 366.6 billion by 2034, rising at a compound annual growth rate (CAGR) of 14.54% from 2024 to 2034.
Top Companies in the Biomarkers:
- Abbott
- Alto Neuroscience, Inc.
- Hanmi Pharmaceutical
- Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Labcorp Biopharma
- MEDiC Life Sciences
- Qiagen
- Regeneron
- Sanofi
- Siemens Healthineers
- Thermo Fisher Scientific
Latest Announcements by Industry Leaders
Rinol Alaj, Senior Director of Digital Health Technologies at Regeneron, commented that many companies are working independently on building digital biomarkers. Hence, the company organized the Digital Biomarkers Summit in May 2024, which could be a terrific opportunity to bring the industry together and create a mechanism of collaboration to help accelerate overall digital biomarker adoption. He also explained that researching digital biomarkers requires change management, innovative thinking/frameworks, and novel ways of problem-solving.
Recent Developments in the Biomarkers Market
- In October 2024, researchers from the Walter and Eliza Hall Institute investigated the role of extracellular vesicles as biomarkers in cancer treatment. They found that there were abnormally high levels of extracellular vesicles in the blood of mice with leukemia.
- In October 2024, researchers from Nationwide Children’s identified a potential biomarker to examine the presence of single ventricle heart disease (SVHD) in a fetus based on a maternal blood test. They found elevated levels of cell-free miRNAs in the blood of mothers carrying a baby with an SVHD.
If you have any questions, please feel free to contact us at
